<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878382</url>
  </required_header>
  <id_info>
    <org_study_id>08/2016</org_study_id>
    <nct_id>NCT02878382</nct_id>
  </id_info>
  <brief_title>Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT</brief_title>
  <acronym>PDT</acronym>
  <official_title>Efficacy of Calcipotriol Assisted MAL-PDT Versus Conventional MAL-PDT for Actinic Keratosis: a Randomized and Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In topical photodynamic therapy (PDT) for non-melanoma skin cancers, a photosensitizing&#xD;
      prodrug, 5-aminolaevulinic acid (ALA) or its methylated ester, methyl aminolevulinate (MAL),&#xD;
      is converted to the endogenous photosensitizer protoporphyrinIX (PpIX).&#xD;
&#xD;
      Reduced response rates are observed in thicker skin lesions, which may be due to insufficient&#xD;
      PpIX accumulation within the target tissue.&#xD;
&#xD;
      To enhance PpIX production,several physical and chemical pretreatments have been suggested.&#xD;
      One of the chemical substances proposed to stimulate PpIX production is vitamin D because of&#xD;
      its ability of being a keratinocyte pro-differentiating hormone.&#xD;
&#xD;
      Based on in vitro and in animal model studies, we propose to study the potential impact of&#xD;
      patient vitamin D pre-treatment in AK response to MAL-PDT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, controlled Split -scalp study with Calcipotriol Assisted MAL-PDT versus&#xD;
      conventional MAL-PDT for actinic keratosis (AK) is proposed.&#xD;
&#xD;
      Twenty patients ( male gender only) with symmetrically distributed multiple AK lesions on the&#xD;
      scalp will be included. Patients must have at least five AKs per field to be eligible.&#xD;
&#xD;
      After simple randomization, one half of the scalp will be treated with Calcipotriol ointment&#xD;
      50 mcg/g (Daivonex, Leo Pharma, Denmark) for 15 consecutive days.&#xD;
&#xD;
      After this period, the entire scalp will be submitted to topical PDT with&#xD;
      Methylaminolevulinate 16% (Metvix, Galderma France) under occlusion for 90 minutes and then,&#xD;
      illuminated with a light source consisting of a Light Emitting Diode device (LED) at 635 nm (&#xD;
      Aktilite - Photocure, Norway). The total light dose will be 37J/cm2.&#xD;
&#xD;
      Immediately before and after illumination with LED, measurements of the fluorescence&#xD;
      intensity will be taken in 3 isolated spots in both sides of the scalp with a spectroscopy&#xD;
      deviceUSB 2000+ ( Ocean Optics Â® - Dunedin, Fl, USA).&#xD;
&#xD;
      AK lesions will be counted and mapped by a dermatologist not involved in the study before and&#xD;
      after 3 months.&#xD;
&#xD;
      All patients will be advised to apply sunscreens 50 + 3x/day for the following 7 days after&#xD;
      the procedure.&#xD;
&#xD;
      A 0-10 Visual Analogue Scale (VAS) will be used to measure the pain intensity during the&#xD;
      illumination.&#xD;
&#xD;
      Records will be taken after 90 days and compared between sides: side effects, AK lesion&#xD;
      response and pain level intensity. Also, a long term follow up will be provided at 6 and 12&#xD;
      months after.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline in Actinic Keratosis - Lesion Base Count.</measure>
    <time_frame>Change from baseline, 90 days, 180 days and 12 months after the PDT</time_frame>
    <description>To compare the efficacy of topical PDT alone versus Calcipotriol assisted PDT for AKs on the scalp.&#xD;
The values in the data table represent the mean (+sd) number of lesions on each side at 3, 6 and 12 months post intervention.&#xD;
Lesion counts include lesions that have not been cleared and also newly emerged lesions ( if new lesions emerge on the treated field) At baseline: number of AKs was 290 on the CAL-PDT side and 284 on the conventional side.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Actinic Keratosis (AK) Lesions Cleared</measure>
    <time_frame>Change from baseline, 90 days, 6 months and 12 months after PDT</time_frame>
    <description>AK clearance after PDT and comparison between the sides The values in the data table represent the percentage of AK clearance on each side at 3, 6 and 12 months post intervention.&#xD;
At baseline: 290 on the CAL-PDT side and 284 on the conventional side.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores Immediately Post Illumination</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Measurement of pain during LED illumination and comparison between the sides with a visual analogue scale (VAS), considering 0 as absence of pain and 10 as the most severe pain.&#xD;
At baseline, before the illumination, there is an absence of pain, which means Score 0 (zero) for all participants before the procedure.&#xD;
Pain is reffered during and after the illumination and measured with the VAS scale, reported by each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fluorescence Intensity of PPIX</measure>
    <time_frame>Baseline and 10 minutes after illumination</time_frame>
    <description>Measurement of PPIX fluorescence on both sides of the scalp before and immediately after LED illumination PpIX fluorescence was measured in three different spot areas on the scalp before and immediately after PDT on each side.&#xD;
The measurements were taken noninvasively in the areas where PpIX fluorescence was more intense, with a handheld fluorescence photometer (USB 2000+ spectroscopy device; Ocean Optics, Dunedin, FL, U.S.A.). The photometer illuminates a circular skin area with a diameter of 1 cm with blue light (400-420 nm), matching the Soret band of PpIX at 405-420 nm. By measuring excitation wavelengths at 600- 700 nm, the corresponding red PpIX fluorescence intensity at 633 nm is detected. Measurements were taken in arbitrary units. The mean PpIX fluorescence value for each side was calculated before and after the treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Conventional MAL-PDT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol assisted MAL-PDT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional MAL-PDT</intervention_name>
    <description>Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose</description>
    <arm_group_label>Conventional MAL-PDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcipotriol assisted MAL-PDT</intervention_name>
    <description>Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose</description>
    <arm_group_label>Calcipotriol assisted MAL-PDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male gender&#xD;
&#xD;
          -  at least six AKs per field&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of photosensitivity related disorders&#xD;
&#xD;
          -  active infectious disease,&#xD;
&#xD;
          -  immunosuppression&#xD;
&#xD;
          -  laser or any cosmetic treatment in the previous 6 months&#xD;
&#xD;
          -  other topical agents in the treatment area such as retinoids, 5-fluorouracil,imiquimod&#xD;
             or diclofenac sodium in the previous 3 months&#xD;
&#xD;
          -  allergy to MAL or excipients of the cream&#xD;
&#xD;
          -  poor patient compliance.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis A Torezan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas FMUSP Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04543120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clinicas Universidade Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <results_first_submitted>May 25, 2020</results_first_submitted>
  <results_first_submitted_qc>July 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2020</results_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Luis Antonio Torezan</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>PDT</keyword>
  <keyword>skin cancer</keyword>
  <keyword>calcipotriol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All twenty patients completed the 12 -month study. Patients were male, Fitzpatrick skin types I-III and mean age 73.8 years (range 54-89).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Calcipotriol Assisted MAL-PDT</title>
          <description>Calcipotriol + MAL-PDT half scalp</description>
        </group>
        <group group_id="P2">
          <title>Conventional MAL-PDT</title>
          <description>MAL-PDT alone half scalp</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20">total 20 patients.split-scalp: 20 split -scalp received CAL-PDT and the other 20 received C-PDT</participants>
                <participants group_id="P2" count="20">otal 20 patients.split-scalp: 20 split -scalp received CAL-PDT and the other 20 received C-PDT</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>20 male patients were selected and enrolled in the study. The eligibility criteria were: male sex, minimum age of 50 years old, at least 6 AKs symmetrically distributed on the scalp, only AKs grades I and II and immunocompetent patients. To receive either Conventional PDT or CAL-PDT on the allocated side of the scalp (right or left)</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.&#xD;
Conventional MAL-PDT: Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose&#xD;
Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT Calcipotriol assisted MAL-PDT: Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of AKs at baseline</title>
          <description>AKs were clinically divided in 2 categories: grade I and grade II, based on Olsen et al classification. Grade I is a thinner lesion. Grade II is a thicker lesion. Both types co-exist on the same patient and reflects the skin photodamage.</description>
          <units>number of lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CAL-PDT side</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conventional PDT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAL-PDT side grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAL-PDT side grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conventional PDT grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conventional PDT grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Actinic Keratosis - Lesion Base Count.</title>
        <description>To compare the efficacy of topical PDT alone versus Calcipotriol assisted PDT for AKs on the scalp.&#xD;
The values in the data table represent the mean (+sd) number of lesions on each side at 3, 6 and 12 months post intervention.&#xD;
Lesion counts include lesions that have not been cleared and also newly emerged lesions ( if new lesions emerge on the treated field) At baseline: number of AKs was 290 on the CAL-PDT side and 284 on the conventional side.</description>
        <time_frame>Change from baseline, 90 days, 180 days and 12 months after the PDT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Assisted MAL-PDT</title>
            <description>Calcipotriol 15 days before - once a day intervention: MAL-PDT plus curettage Illumination LED 635 nm 37J/cm2</description>
          </group>
          <group group_id="O2">
            <title>Conventional MAL-PDT</title>
            <description>intervention: MAL-PDT plus curettage Illumination LED 635 nm 37J/cm2</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Actinic Keratosis - Lesion Base Count.</title>
          <description>To compare the efficacy of topical PDT alone versus Calcipotriol assisted PDT for AKs on the scalp.&#xD;
The values in the data table represent the mean (+sd) number of lesions on each side at 3, 6 and 12 months post intervention.&#xD;
Lesion counts include lesions that have not been cleared and also newly emerged lesions ( if new lesions emerge on the treated field) At baseline: number of AKs was 290 on the CAL-PDT side and 284 on the conventional side.</description>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.99"/>
                    <measurement group_id="O2" value="2.65" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.93"/>
                    <measurement group_id="O2" value="2.60" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="1.04"/>
                    <measurement group_id="O2" value="3.20" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>significance level of 5%</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>also, Fisher's exact test and Mann-Whtiney were used for comparing the other variables in the study</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Actinic Keratosis (AK) Lesions Cleared</title>
        <description>AK clearance after PDT and comparison between the sides The values in the data table represent the percentage of AK clearance on each side at 3, 6 and 12 months post intervention.&#xD;
At baseline: 290 on the CAL-PDT side and 284 on the conventional side.</description>
        <time_frame>Change from baseline, 90 days, 6 months and 12 months after PDT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Assisted MAL-PDT</title>
            <description>Calcipotriol 15 days before - once a day intervention: MAL-PDT plus curettage Illumination LED 635 nm 37J/cm2</description>
          </group>
          <group group_id="O2">
            <title>Conventional MAL-PDT</title>
            <description>intervention: MAL-PDT plus curettage Illumination LED 635 nm 37J/cm2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Actinic Keratosis (AK) Lesions Cleared</title>
          <description>AK clearance after PDT and comparison between the sides The values in the data table represent the percentage of AK clearance on each side at 3, 6 and 12 months post intervention.&#xD;
At baseline: 290 on the CAL-PDT side and 284 on the conventional side.</description>
          <units>percentage of lesions cleared</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores Immediately Post Illumination</title>
        <description>Measurement of pain during LED illumination and comparison between the sides with a visual analogue scale (VAS), considering 0 as absence of pain and 10 as the most severe pain.&#xD;
At baseline, before the illumination, there is an absence of pain, which means Score 0 (zero) for all participants before the procedure.&#xD;
Pain is reffered during and after the illumination and measured with the VAS scale, reported by each patient.</description>
        <time_frame>immediately after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Assisted MAL-PDT</title>
          </group>
          <group group_id="O2">
            <title>Conventional MAL-PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores Immediately Post Illumination</title>
          <description>Measurement of pain during LED illumination and comparison between the sides with a visual analogue scale (VAS), considering 0 as absence of pain and 10 as the most severe pain.&#xD;
At baseline, before the illumination, there is an absence of pain, which means Score 0 (zero) for all participants before the procedure.&#xD;
Pain is reffered during and after the illumination and measured with the VAS scale, reported by each patient.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.4"/>
                    <measurement group_id="O2" value="4.0" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.001</p_value>
            <p_value_desc>significance level of 5%</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fluorescence Intensity of PPIX</title>
        <description>Measurement of PPIX fluorescence on both sides of the scalp before and immediately after LED illumination PpIX fluorescence was measured in three different spot areas on the scalp before and immediately after PDT on each side.&#xD;
The measurements were taken noninvasively in the areas where PpIX fluorescence was more intense, with a handheld fluorescence photometer (USB 2000+ spectroscopy device; Ocean Optics, Dunedin, FL, U.S.A.). The photometer illuminates a circular skin area with a diameter of 1 cm with blue light (400-420 nm), matching the Soret band of PpIX at 405-420 nm. By measuring excitation wavelengths at 600- 700 nm, the corresponding red PpIX fluorescence intensity at 633 nm is detected. Measurements were taken in arbitrary units. The mean PpIX fluorescence value for each side was calculated before and after the treatment.</description>
        <time_frame>Baseline and 10 minutes after illumination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Calcipotriol Assisted MAL-PDT</title>
          </group>
          <group group_id="O2">
            <title>Conventional MAL-PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fluorescence Intensity of PPIX</title>
          <description>Measurement of PPIX fluorescence on both sides of the scalp before and immediately after LED illumination PpIX fluorescence was measured in three different spot areas on the scalp before and immediately after PDT on each side.&#xD;
The measurements were taken noninvasively in the areas where PpIX fluorescence was more intense, with a handheld fluorescence photometer (USB 2000+ spectroscopy device; Ocean Optics, Dunedin, FL, U.S.A.). The photometer illuminates a circular skin area with a diameter of 1 cm with blue light (400-420 nm), matching the Soret band of PpIX at 405-420 nm. By measuring excitation wavelengths at 600- 700 nm, the corresponding red PpIX fluorescence intensity at 633 nm is detected. Measurements were taken in arbitrary units. The mean PpIX fluorescence value for each side was calculated before and after the treatment.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3422.85" spread="1775.19"/>
                    <measurement group_id="O2" value="2688.35" spread="1746.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Student's t-test or the Mann-Whitney test was used according to the assumption of normality of data for PpIX fluorescence intensity</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.048</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>side effects collected over 10 days</time_frame>
      <desc>During light exposure patients were asked to evaluate the intensity of pain using a visual analogue scale (VAS), considering 0 as absence of pain and 10 as the most severe pain. Local skin reactions (erythema, edema, pustules, crusts, erosions and ulcerations) were recorded as well as any systemic adverse events during treatment and after follow-up visits. Clinical assessments of the local skin reactions were performed on a pre-defined scale as: 0 = no reaction, + mild, ++ moderate, +++ severe</desc>
      <group_list>
        <group group_id="E1">
          <title>Calcipotriol Assisted MAL-PDT</title>
          <description>Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT&#xD;
Calcipotriol assisted MAL-PDT: Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose</description>
        </group>
        <group group_id="E2">
          <title>Conventional MAL-PDT</title>
          <description>Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.&#xD;
Conventional MAL-PDT: Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>local skin reactions</sub_title>
                <description>erythema, edema, crusts and pustules.</description>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="20"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Luis Torezan Associate Professor Dermatology</name_or_title>
      <organization>University of Sao Paulo Medical School Brazil</organization>
      <phone>+551138491888</phone>
      <email>torezanluis@uol.com.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

